spondyloarthropathy: A group of inflammatory rheumatic diseases associated with arthritis and enthesitis, and often involving the axial skeleton. The most common form of spondyloarthritis is ankylosing spondylitis. Other forms include axial spondyloarthritis, peripheral spondyloarthritis, reactive arthritis, psoriatic arthritis/spondylitis and enteropathic arthritis/spondylitis.
Spondylopathies in diseases classified elsewhere
DOID EFO Endpoint Browser PheWeb
M13_SPONDYLOPATHINOTH
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
410 |
4. Check minimum number of eventsNone |
410 |
5. Include endpointsNone |
410 |
6. Filter based on genotype QC (FinnGen only) |
410 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Spondylopathies in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Spondylopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2934 | 1388 | 1517 |
| Only index persons | 2404 | 1175 | 1229 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.05 | 0.04 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 67.32 | 67.49 | 67.19 |
| Only index persons | 67.27 | 67.47 | 67.08 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 410 | 188 | 222 |
| Unadjusted period prevalence (%) | 0.08 | 0.06 | 0.10 |
| Median age at first event (years) | 68.19 | 65.83 | 70.19 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 383
- Matched controls
- 3828
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
+∞
217.0
187
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
71.1
117.4
132
28
N02AA05
ATC
oxycodone; systemic
16.0
112.4
212
275
WF049
NOMESCO Finland
Radiotherapy of metastasis
37.8
109.3
141
58
H02AB02
ATC
dexamethasone; systemic
10.9
75.4
165
248
C90.0
ICD-10 Finland
Multiple myeloma
57.6
70.2
82
18
M48.0
ICD-10 Finland
Spinal stenosis
55.1
61.2
72
16
M49.5*C90.0
ICD-10 Finland
Vertebral fracture due to multiple myeloma
+∞
60.0
56
*
M05BX04
ATC
denosumab; parenteral
16.3
57.7
97
78
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
16.2
55.4
93
74
N03AX16
ATC
pregabalin; oral
7.2
53.6
153
323
153
Kela drug reimbursment
Lenalidomid
95.5
52.6
57
7
9732/3-C42.1
ICD-O-3
Plasma cell myeloma of bone marrow
60.6
49.3
57
11
L04AX04
ATC
lenalidomide; oral
120.0
49.1
52
5
M49.5
ICD-10 Finland
Collapsed vertebra in diseases classified elsewhere
+∞
49.0
46
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
14.3
48.7
86
76
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.0
46.6
223
840
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
28.9
42.1
57
23
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
11.2
41.9
83
92
A04AA01
ATC
ondansetron; systemic, rectal
9.1
41.7
94
132
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
41.8
41.2
51
14
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
26.5
41.1
57
25
Z51.5
ICD-10 Finland
Palliative care
9.3
41.0
91
124
N03AX12
ATC
gabapentin; oral
8.2
39.4
95
148
M54.5
ICD-10 Finland
Low back pain
5.3
38.7
140
373
A03FA01
ATC
metoclopramide; systemic, rectal
4.5
35.8
161
531
N02AX02
ATC
tramadol; systemic, rectal
4.0
35.4
211
899
M54.9
ICD-10 Finland
Dorsalgia, unspecified
11.6
35.3
68
70
WF004
NOMESCO Finland
Palliative radiotherapy
19.4
35.3
54
32
329
Kela drug reimbursment
Lenalidomide
81.4
33.5
37
5
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
356.2
33.4
33
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
10.9
33.2
66
72
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.9
33.1
192
786
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
60.0
32.9
38
7
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
32.1
32.8
43
15
XX3DW
NOMESCO Finland
Time consuming IT work
5.8
32.3
103
230
JN4BD
NOMESCO Finland
Extensive body CT
5.3
32.1
111
273
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
12.7
30.7
56
51
M49.0*A18.0
ICD-10 Finland
Tuberculosis of spine
+∞
29.6
28
*
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
30.8
29.5
39
14
NJ3DA
NOMESCO Finland
Long bones of extremities X-ray examination
71.9
29.4
33
5
JN4AD
NOMESCO Finland
Body CT examination
6.3
29.0
83
160
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
28.7
234
1205
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
25.4
28.0
39
17
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.8
27.6
104
276
A02BC02
ATC
pantoprazole; systemic
3.5
26.7
287
1772
AA1AA
NOMESCO Finland
Head X-ray examination
39.9
26.6
33
9
M49.4*G95.0
ICD-10 Finland
Neuropathic spondylopathy in syringomyelia and syringobulbia
+∞
26.4
25
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
19.6
25.9
39
22
ZX112
NOMESCO Finland
Subcutaneous
12.6
25.4
46
41
L03AA02
ATC
filgrastim; parenteral
11.8
25.1
47
45
ZX120
NOMESCO Finland
Intravenous
5.2
24.7
84
197
WW300
NOMESCO Finland
Transfer of autologic stem cells
72.3
24.1
27
*
G95.0
ICD-10 Finland
Syringomyelia and syringobulbia
255.3
23.9
24
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
57.9
23.4
27
5
M54.4
ICD-10 Finland
Lumbago with sciatica
7.0
23.3
60
99
A06AD11
ATC
lactulose; oral
4.1
23.2
102
309
NAG53
NOMESCO Finland
Posterior or lateral fusion of thoracic spine with fixation, more than 3 vertebraea
+∞
23.2
22
*
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
127.7
22.8
24
*
XW000
NOMESCO Finland
Bone marrow biopsy
7.6
22.4
54
81
130
Kela drug reimbursment
Malignant tumour
4.7
22.0
82
211
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
232.7
21.8
22
*
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
30.1
21.3
28
10
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
16.1
21.1
34
23
NK6AN
NOMESCO Finland
Total body bone isotope imaging
8.7
21.0
46
59
TPH04
NOMESCO Finland
Cathetrisation of vein
3.3
20.2
123
480
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
77.4
19.9
22
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
26.3
19.8
27
11
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
33.3
19.5
25
8
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
5.1
19.3
64
144
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
73.7
18.9
21
*
393
Kela drug reimbursment
Pomalidomide
199.4
18.7
19
*
R50.9
ICD-10 Finland
Fever, unspecified
3.8
18.2
84
261
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
5.3
17.8
56
119
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.4
17.7
55
115
M84.4
ICD-10 Finland
Pathological fracture, not elsewhere classified
188.4
17.7
18
*
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
30.5
17.6
23
8
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
6.5
17.3
46
79
L03
ICPC
Low back symptom/complaint
3.4
17.1
94
335
A06AH03
ATC
naloxegol; oral
23.2
17.1
24
11
1507
Kela drug reimbursment
Pomalidomide
177.4
16.6
17
*
M90.7*C90.0
ICD-10 Finland
Pathological fracture in multiple myeloma
177.4
16.6
17
*
L04AX06
ATC
pomalidomide; oral
177.4
16.6
17
*
L28
ICPC
Limited function/disability (L)
3.4
16.4
90
319
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.3
16.4
95
352
B01AB05
ATC
enoxaparin; parenteral
2.6
16.2
151
756
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
25.8
16.2
22
9
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
62.8
15.9
18
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
10.8
15.7
30
30
NAR00
NOMESCO Finland
Complete excision of tumour of bone or cartilage of spine, unspecified
+∞
15.7
15
*
WW500
NOMESCO Finland
Blood transfusion
5.9
15.7
45
85
WX2DD
NOMESCO Finland
Low-dose CT of skeleton in whole body
88.8
15.7
17
*
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
47.0
15.2
18
*
N02AJ06
ATC
codeine and paracetamol; systemic
2.6
15.0
139
688
116
Kela drug reimbursment
Prostate cancer
4.4
15.0
57
147
L01AA03
ATC
melphalan; systemic
59.1
14.9
17
*
WZC30
NOMESCO Finland
Teaching
3.4
14.9
80
277
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
16.2
14.6
23
15
YNB10
NOMESCO Finland
Collection of stem cells for transplant
155.7
14.6
15
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.6
14.3
132
646
163
Kela drug reimbursment
Abiraterone and enzalutamide
15.2
14.2
23
16
NA2AD
NOMESCO Finland
Thoracic spine CT examination
44.3
14.2
17
*
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.1
13.9
88
341
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.3
13.7
52
134
M47.9
ICD-10 Finland
Spondylosis, unspecified
35.5
13.6
17
5
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
17.0
13.6
21
13
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
144.9
13.5
14
*
SPAT1229
SPAT
Assessment of need for aid
4.1
13.4
54
147
N02BE01
ATC
paracetamol; systemic, rectal
2.8
13.2
328
2612
L86
ICPC
Back syndrome with radiating pain
8.5
13.1
28
35
S22.0
ICD-10 Finland
Fracture of thoracic vertebra
11.1
12.9
24
23
A28
ICPC
Limited function/disability NOS
2.9
12.7
85
339
A04AA02
ATC
granisetron; systemic, transdermal
4.3
12.7
48
123
1501
Kela drug reimbursment
Palbociclib
72.3
12.7
14
*
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
72.3
12.7
14
*
WW402
NOMESCO Finland
Leucoferesis
72.3
12.7
14
*
ABC56
NOMESCO Finland
Decompression of lumbar spinal canal and nerve roots
+∞
12.6
12
*
197
Kela drug reimbursment
Sunitinib
134.2
12.5
13
*
J01MA12
ATC
levofloxacin; systemic
2.6
12.4
102
463
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
7.5
12.0
28
40
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
9.4
11.9
24
27
M03BX02
ATC
tizanidine; oral
2.2
11.9
202
1305
J05AB01
ATC
aciclovir; systemic
2.6
11.9
97
437
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.2
11.5
154
889
NAG63
NOMESCO Finland
Posterior fusion of lumbar spine with fixation, more than 3 vertebraea
+∞
11.5
11
*
A18.0
ICD-10 Finland
Tuberculosis of bones and joints
+∞
11.5
11
*
394
Kela drug reimbursment
Palbociclib
123.6
11.5
12
*
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
12.3
11.5
20
17
M80.9
ICD-10 Finland
Unspecified osteoporosis with pathological fracture
11.0
11.4
21
20
1XX32
NOMESCO Finland
NA
36.2
11.3
14
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
13.3
11.3
19
15
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
20.8
11.2
16
8
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.9
11.2
72
281
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
10.9
90
407
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
5.6
10.9
31
59
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
18.5
10.8
16
9
C03CA01
ATC
furosemide; systemic
2.2
10.8
148
861
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
13.4
10.8
18
14
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
7.4
10.8
25
36
M43.1
ICD-10 Finland
Spondylolisthesis
61.8
10.7
12
*
WW409
NOMESCO Finland
Other aferesis
61.8
10.7
12
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
6.5
10.7
27
44
M01AE01
ATC
ibuprofen; systemic, rectal
2.4
10.6
320
2593
M04AA01
ATC
allopurinol; systemic
2.6
10.5
80
347
S32.0
ICD-10 Finland
Fracture of lumbar vertebra
7.5
10.4
24
34
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
16.6
10.4
16
10
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.8
10.4
70
280
5BA08
NOMESCO Finland
NA
24.1
10.3
14
6
M54.6
ICD-10 Finland
Pain in thoracic spine
7.0
10.1
24
36
J05AB11
ATC
valaciclovir; oral
3.0
10.1
62
235
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
9.1
9.9
20
23
L02BA03
ATC
fulvestrant; parenteral
20.7
9.9
14
7
L02BB04
ATC
enzalutamide; oral
13.9
9.8
16
12
H02AB06
ATC
prednisolone; systemic
2.0
9.7
184
1206
M03BC01
ATC
orphenadrine (citrate); systemic
2.6
9.6
77
340
ZZH31
NOMESCO Finland
Bone allograft, small pieces
15.5
9.6
15
10
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.4
9.6
46
146
M05BA02
ATC
clodronic acid; systemic
18.1
9.5
14
8
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
8.4
9.5
20
25
L01XE33
ATC
[U] palbociclib; oral
102.5
9.5
10
*
1502
Kela drug reimbursment
Cabozantinib
102.5
9.5
10
*
L01XE04
ATC
[U] sunitinib; oral
102.5
9.5
10
*
3012
Kela drug reimbursment
Cabozantinib
102.5
9.5
10
*
M48.5
ICD-10 Finland
Collapsed vertebra, not elsewhere classified
+∞
9.4
9
*
ABC16
NOMESCO Finland
Microsurgical excision of lumbar intervertebral disc displacement
+∞
9.4
9
*
398
Kela drug reimbursment
Ixazomib
+∞
9.4
9
*
7227C
ICD-9 Finland
Intervertebral disk disorders, Intervertebral disk disorder with myelopathy[SYNDROMA ISCHIADICUM]
+∞
9.4
9
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
5.7
9.4
26
48
NA1AD
NOMESCO Finland
Cervical spine CT examination
6.0
9.4
25
44
NE1AA
NOMESCO Finland
Pelvis X-ray examination
3.7
9.4
41
121
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.0
9.3
184
1222
L03AA13
ATC
pegfilgrastim; parenteral
4.8
9.3
30
66
SPAT1255
SPAT
Intravenous administration of medicine
3.8
9.3
39
111
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.1
9.2
52
185
L02BB03
ATC
bicalutamide; oral
5.1
9.2
28
58
R11
ICD-10 Finland
Nausea and vomiting
3.6
9.2
41
123
GA5AA
NOMESCO Finland
Rib X-ray examination
19.2
9.0
13
7
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
13.0
8.9
15
12
M54.8
ICD-10 Finland
Other dorsalgia
11.1
8.9
16
15
TPH07
NOMESCO Finland
Cathetrisation of artery
2.8
8.8
58
228
R06AE07
ATC
cetirizine; oral
2.0
8.8
145
892
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
7.2
8.7
20
29
SPAT1254
SPAT
Administration of medicine
2.5
8.7
71
316
ZX108
NOMESCO Finland
Inhalation
28.2
8.5
11
*
192
Kela drug reimbursment
Fulvestrant
20.6
8.5
12
6
J01MA02
ATC
ciprofloxacin; systemic
1.9
8.5
161
1040
G55.1*M51.1
ICD-10 Finland
Compression of nerve roots and nerve plexus in disc diseases in the lumbar region and other regions
92.0
8.4
9
*
M43.0
ICD-10 Finland
Spondylolysis
92.0
8.4
9
*
L02BX03
ATC
abiraterone; oral
13.2
8.4
14
11
WX408
NOMESCO Finland
General anesthesy, balanced
2.1
8.4
115
655
C61
ICD-10 Finland
Malignant neoplasm of prostate
2.5
8.4
67
295
1505
Kela drug reimbursment
Ixazomib
+∞
8.4
8
*
ABC53
NOMESCO Finland
Decompression of thoracic spinal canal and nerve roots
+∞
8.4
8
*
NAG40
NOMESCO Finland
Anterior fusion of cervical spine without fixation
+∞
8.4
8
*
M46.4
ICD-10 Finland
Discitis, unspecified
+∞
8.4
8
*
M41.5
ICD-10 Finland
Other secondary scoliosis
+∞
8.4
8
*
NAG62
NOMESCO Finland
Posterior fusion of lumbar spine with fixation, 2-3 vertebraea
+∞
8.4
8
*
AA1AD
NOMESCO Finland
CT of head and brain
2.1
8.3
104
570
JN4CD
NOMESCO Finland
Very extensive body CT
4.3
8.3
30
75
M47.82
ICD-10 Finland
Other spondylosis, cervical region
14.9
8.3
13
9
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.6
8.3
62
265
M01AH05
ATC
etoricoxib; oral
1.9
8.2
194
1352
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
2.6
8.1
63
272
A04
ICPC
Weakness/tiredness general
2.7
8.1
55
221
G82.2
ICD-10 Finland
Paraplegia, unspecified
34.1
8.1
10
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.3
8.0
40
132
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
5.9
7.9
21
37
M81.9
ICD-10 Finland
Osteoporosis, unspecified
5.9
7.9
21
37
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
9.7
7.8
15
16
352
Kela drug reimbursment
Abiraterone and enzalutamide
15.4
7.8
12
8
N06AX21
ATC
duloxetine; oral
3.4
7.8
36
112
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
7.7
7.8
17
23
C90.2
ICD-10 Finland
Extramedullary plasmacytoma
45.9
7.7
9
*
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.9
7.7
153
998
A07AA02
ATC
nystatin; oral
3.7
7.7
32
91
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
18.8
7.6
11
6
M54.1
ICD-10 Finland
Radiculopathy
12.2
7.6
13
11
N06AA09
ATC
amitriptyline; systemic
3.1
7.6
40
137
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.0
7.5
114
672
G04BD04
ATC
oxybutynin; oral, transdermal
3.7
7.5
31
88
NAJ22
NOMESCO Finland
Posterior reduction of fractrue of thoracic spine
81.6
7.4
8
*
L01XE26
ATC
[U] cabozantinib; oral
81.6
7.4
8
*
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
81.6
7.4
8
*
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
11.2
7.3
13
12
Y77
ICPC
Malignant neoplasm prostate
4.1
7.3
27
69
XKD06
NOMESCO Finland
Physiologic investigation of micturition
5.6
7.3
20
37
M45
ICD-10 Finland
Ankylosing spondylitis
+∞
7.3
7
*
M47.1
ICD-10 Finland
Other spondylosis with myelopathy
+∞
7.3
7
*
M49.0
ICD-10 Finland
Tuberculosis of spine
+∞
7.3
7
*
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
2.9
7.2
45
170
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
4.2
7.2
26
65
XKC03
NOMESCO Finland
Water cystometry
5.5
7.2
20
38
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.5
7.2
58
258
L02BX02
ATC
degarelix; parenteral
9.0
7.1
14
16
L02BG06
ATC
exemestane; oral
7.2
7.1
16
23
AA1BD
NOMESCO Finland
Extensive CT of head and brain
4.8
7.0
22
48
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
5.7
7.0
19
35
E0000UV
ATC
NA
1.8
7.0
139
902
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.6
6.9
50
206
X59
ICD-10 Finland
Exposure to unspecified factor
2.3
6.9
70
345
NF3AA
NOMESCO Finland
Femur X-ray examination
5.8
6.8
18
32
N07BC02
ATC
methadone; systemic
40.8
6.8
8
*
ZXM20
NOMESCO Finland
Intraoperative use of computerised tomography
40.8
6.8
8
*
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
17.1
6.8
10
6
M05BA04
ATC
alendronic acid; oral
2.9
6.8
39
142
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.2
6.7
73
374
A79
ICPC
Malignancy NOS
6.6
6.7
16
25
R4110
NOMESCO Finland
Physiotherapy
2.0
6.7
103
607
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.3
6.6
62
296
B01AB10
ATC
tinzaparin; parenteral
2.8
6.6
41
155
1CX01
NOMESCO Finland
NA
71.0
6.4
7
*
M41.9
ICD-10 Finland
Scoliosis, unspecified
71.0
6.4
7
*
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
14.6
6.4
10
7
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
6.1
6.4
16
27
UKC02
NOMESCO Finland
Cystoscopy
2.1
6.3
76
406
L02AE02
ATC
leuprorelin; implant, parenteral
3.1
6.3
32
108
M48.9
ICD-10 Finland
Spondylopathy, unspecified
+∞
6.3
6
*
M49
ICD-10 Finland
Spondylopathies in diseases classified elsewhere
+∞
6.3
6
*
L04AX02
ATC
thalidomide; oral
+∞
6.3
6
*
G95.2
ICD-10 Finland
Cord compression, unspecified
+∞
6.3
6
*
M49.1*A23.9
ICD-10 Finland
Brucella spondylitis
+∞
6.3
6
*
M41.2
ICD-10 Finland
Other idiopathic scoliosis
+∞
6.3
6
*
ABC63
NOMESCO Finland
Decompression of thoracic spinal cord
+∞
6.3
6
*
R60.0
ICD-10 Finland
Localized oedema
2.6
6.3
46
192
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.7
6.2
163
1144
R52.2
ICD-10 Finland
Other chronic pain
6.5
6.2
15
24
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.7
6.2
25
70
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
3.2
6.2
31
103
XKD03
NOMESCO Finland
Urethral pressure profilometry
5.9
6.2
16
28
L02BG04
ATC
letrozole; oral
3.2
6.2
30
98
R53
ICD-10 Finland
Malaise and fatigue
2.1
6.2
73
387
M54.2
ICD-10 Finland
Cervicalgia
4.5
6.1
20
46
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
3.0
6.1
33
116
SPAT1245
SPAT
Provision of support and information to patient’s family members
3.5
6.1
26
77
NE1AD
NOMESCO Finland
Pelvis and hip bones CT examination
5.7
6.1
16
29
A03FA02
ATC
cisapride; oral, rectal
2.8
6.0
36
135
A02BC05
ATC
esomeprazole; systemic
1.8
6.0
142
962
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
95
103
11.70
82.61
21.7
2.6
52.7
134.2
mg/l
0.67
81
81
94
102
11.66
81.65
21.0
2.6
2.7
1.1
ratio
—
8
11
94
103
11.54
81.07
21.9
2.6
30.4
60.1
mg/l
0.50
80
83
154
382
5.85
62.39
9.7
4.3
244.7
250.1
u/l
0.20
149
366
131
284
6.31
61.33
17.2
2.1
64.6
66.6
g/l
2.01
123
257
161
526
4.39
44.62
6.5
3.2
0.8
0.8
mmol/l
1.97
151
490
70
121
6.77
40.27
18.2
1.6
4.0
1.0
g/l
2.11
60
101
72
130
6.51
39.67
18.4
1.3
3.3
3.7
g/l
0.74
43
95
72
131
6.45
39.36
18.4
1.3
7.5
7.3
g/l
0.30
50
97
72
131
6.45
39.36
18.4
1.3
—
—
—
0
0
69
124
6.49
38.14
18.6
1.3
3.1
3.2
g/l
0.07
44
96
303
1659
4.17
37.74
25.4
6.4
1.2
1.2
mmol/l
0.45
257
1379
154
550
3.88
36.63
3.1
1.8
—
—
—
0
0
283
1509
3.83
36.00
19.9
5.7
1.2
1.2
mmol/l
0.32
269
1351
133
439
4.00
35.29
8.5
5.2
1.0
1.0
mmol/l
0.32
120
400
34
28
13.15
34.55
6.0
2.6
—
—
—
0
0
64
122
6.03
33.17
20.2
1.3
8.2
11.0
g/l
2.49
47
102
43
55
8.62
32.10
7.9
5.3
321.8
162.8
iu/ml
—
5
6
51
90
6.33
28.46
2.2
1.7
—
—
—
0
0
48
88
6.05
25.72
2.3
1.7
—
—
—
0
0
294
1808
3.21
25.68
32.7
9.1
3.7
4.2
e9/l
3.58
277
1584
258
1476
3.02
25.68
11.5
5.4
59.5
57.9
%
1.14
251
1391
49
92
5.91
25.62
1.8
1.2
—
—
—
0
0
260
1495
3.02
25.61
12.4
5.6
24.5
26.7
%
2.19
251
1393
214
1113
2.93
25.32
9.4
3.3
2.3
2.4
mmol/l
2.49
194
966
29
30
10.33
25.28
2.7
2.9
—
—
—
0
0
79
227
4.07
24.78
2.3
1.5
—
—
—
0
0
251
1447
2.89
24.05
12.4
4.3
32.5
34.9
g/l
8.31
236
1336
105
380
3.37
23.26
2.8
1.7
—
—
—
0
0
103
369
3.39
23.18
7.9
7.3
5.2
5.1
kpa
0.15
92
359
103
369
3.39
23.18
7.9
7.3
12.3
12.1
kpa
0.14
92
359
104
379
3.34
22.74
7.8
7.2
1.3
1.4
mmol/l
0.11
75
303
103
380
3.28
22.01
2.7
1.7
—
—
—
0
0
30
42
7.63
20.62
1.5
1.6
—
—
—
0
0
62
174
4.02
19.91
1.6
1.3
—
—
—
0
0
38
71
5.80
19.88
2.2
1.8
—
—
—
0
0
26
32
8.61
19.85
1.5
1.7
103.6
109.7
u/ml
—
8
8
30
44
7.28
19.79
2.0
1.7
—
—
—
0
0
290
1919
2.75
19.40
12.5
4.5
6.9
6.8
mmol/l
0.31
272
1795
29
43
7.18
18.94
2.0
1.7
—
—
—
0
0
238
1447
2.54
18.76
7.2
3.8
—
—
—
0
0
85
308
3.22
18.48
8.8
6.2
10.2
10.5
mmol/l
0.15
80
290
85
312
3.18
18.06
8.3
8.1
112.3
120.2
g/l
2.90
78
306
46
112
4.50
17.75
21.5
1.3
37.1
37.9
g/l
0.44
41
91
147
745
2.52
16.74
4.5
2.3
—
—
—
0
0
153
802
2.45
16.08
8.7
2.7
15292.9
5361.1
umol/l
0.45
141
691
172
961
2.36
15.55
6.8
3.2
58.1
31.6
u/l
1.12
165
911
171
972
2.30
14.66
4.2
2.3
45.9
58.3
u/l
6.67
163
894
30
60
5.32
14.54
1.7
1.3
—
—
—
0
0
30
60
5.32
14.54
1.7
1.3
—
—
—
0
0
61
208
3.27
14.50
5.4
6.5
25.6
24.9
mmol/l
0.62
52
200
24
40
6.31
14.01
2.4
1.7
—
—
—
0
0
24
40
6.31
14.01
2.4
1.7
—
—
—
0
0
24
40
6.31
14.01
2.4
1.6
—
—
—
0
0
62
220
3.14
13.77
3.9
4.1
2.0
2.4
mmol/l
0.39
49
173
50
157
3.49
13.51
1.8
2.0
1.1
3.5
ug/l
0.67
42
139
18
7
26.79
13.48
1.2
1.7
—
—
—
0
0
70
271
2.91
13.34
11.6
7.3
1.3
1.3
mmol/l
0.03
64
262
18
23
8.14
13.25
2.6
1.7
—
—
—
0
0
18
23
8.14
13.25
2.6
1.7
—
—
—
0
0
18
23
8.14
13.25
2.6
1.7
—
—
—
0
0
18
23
8.14
13.25
2.6
1.7
—
—
—
0
0
195
1207
2.17
13.21
5.3
3.1
—
—
—
0
0
110
537
2.43
13.16
3.7
1.9
28.7
29.7
s
1.23
105
523
164
958
2.19
12.76
2.7
2.0
113.9
247.8
u/l
2.88
144
894
16
19
8.72
12.45
3.2
1.7
—
—
—
0
0
16
19
8.72
12.45
2.8
1.7
—
—
—
0
0
16
19
8.72
12.45
2.8
1.7
—
—
—
0
0
97
461
2.45
12.22
3.3
2.4
19.6
21.8
%
0.97
84
403
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
37
104
3.81
11.74
2.9
2.3
0.4
0.4
u/ml
0.06
27
56
322
2494
2.36
11.61
26.1
7.3
92.2
80.8
u/l
2.28
314
2314
39
120
3.49
10.84
3.1
2.9
—
—
—
0
0
174
1102
2.01
10.42
3.8
3.1
1273.3
1732.5
ng/l
1.29
151
956
22
45
5.11
10.38
1.5
1.2
—
—
—
0
0
154
938
2.03
10.26
5.2
3.0
0.3
0.6
e6/l
1.24
135
701
69
304
2.53
10.11
7.5
3.6
2.3
1.9
mmol/l
0.31
59
241
195
1301
1.95
9.91
5.4
3.6
43.7
71.6
ng/l
0.46
157
993
25
61
4.30
9.58
1.8
1.6
—
—
—
0
0
27
70
4.06
9.56
1.9
1.4
—
—
—
0
0
74
346
2.39
9.51
7.5
2.5
8.1
8.5
umol/l
0.09
69
305
23
53
4.54
9.45
1.9
1.7
—
—
—
0
0
15
23
6.73
9.41
1.0
1.3
—
—
—
0
0
41
143
3.07
9.32
3.9
4.5
25.1
25.2
mmol/l
0.08
35
137
40
138
3.10
9.26
4.0
1.7
—
—
—
0
0
82
407
2.27
9.17
4.3
4.3
22.0
37.6
ug/l
0.30
63
332
112
629
2.07
9.16
6.1
3.0
2.5
2.5
mmol/l
0.61
101
558
22
52
4.41
8.77
1.5
1.3
—
—
—
0
0
52
219
2.57
8.32
2.3
1.5
—
—
—
0
0
108
625
1.99
8.02
2.5
1.6
1.3
1.5
mg/l
0.29
86
502
36
128
2.99
7.92
2.9
1.5
—
—
—
0
0
22
58
3.95
7.63
1.8
1.7
—
—
—
0
0
18
41
4.55
7.50
1.9
1.8
—
—
—
0
0
132
843
1.83
7.16
2.3
2.0
3.5
3.1
mg/l
0.63
116
711
35
130
2.85
7.13
1.7
3.0
254.8
74.1
u/ml
0.64
35
123
13
23
5.80
7.11
1.4
1.1
—
—
—
0
0
17
39
4.50
7.02
1.3
1.4
9611.6
28092.5
e6/l
—
10
21
91
520
1.96
6.91
5.1
2.9
3.4
2.2
e6/l
0.42
60
286
19
49
4.02
6.78
3.8
2.3
33.9
32.8
pg
0.63
19
49
10
6
17.04
6.77
1.0
1.0
—
—
—
0
0
10
14
7.30
6.72
3.1
1.2
—
—
—
0
0
12
21
5.86
6.62
3.1
1.4
—
—
—
0
0
12
21
5.86
6.62
3.1
1.4
—
—
—
0
0
26
85
3.20
6.59
1.6
1.3
234.3
288.7
ug/g
0.57
18
54
10
7
14.60
6.42
12.8
4.1
—
—
—
0
0
17
42
4.18
6.42
1.4
1.2
280.6
401.6
u/ml
—
10
21
92
542
1.90
6.35
4.5
2.8
1.0
1.2
e6/l
0.37
61
304
10
15
6.81
6.34
1.4
1.3
24.4
21.1
u/l
—
10
10
12
22
5.59
6.32
1.2
1.4
—
—
—
0
0
34
133
2.70
6.30
5.0
4.7
1.9
1.5
%
1.45
27
128
13
26
5.13
6.26
1.5
1.0
—
—
—
0
0
27
94
3.00
6.17
1.4
1.8
—
—
—
0
0
203
1514
1.68
6.13
5.9
3.6
0.0
0.0
estimate
0.00
39
280
104
645
1.82
6.08
5.2
3.3
59.2
319.3
ng/l
3.28
88
524
180
1303
1.68
6.08
3.5
2.6
245.9
147.1
ug/l
1.94
170
1170
19
54
3.64
5.95
1.6
1.7
—
—
—
0
0
18
50
3.72
5.82
1.9
1.7
—
—
—
0
0
174
1262
1.66
5.75
2.6
2.1
73.8
78.6
nmol/l
1.17
158
1089
10
17
6.00
5.65
3.4
1.5
—
—
—
0
0
10
17
6.00
5.65
3.4
1.5
—
—
—
0
0
56
290
2.08
5.54
2.7
2.9
163.5
225.4
ng/l
0.95
48
263
201
1529
1.62
5.38
6.0
3.6
0.0
0.0
estimate
0.00
38
274
25
91
2.86
5.30
4.4
1.6
91.6
90.2
%
0.16
25
86
199
1519
1.60
5.20
7.8
4.9
0.0
0.0
estimate
0.00
40
287
20
65
3.18
5.14
1.5
1.4
—
—
—
0
0
50
257
2.08
5.05
3.2
3.7
119.1
84.3
ng/l
1.10
44
222
76
466
1.77
4.53
19.2
26.3
1.7
1.4
inr
—
6
65
8
9
9.04
4.29
2.0
1.4
—
—
—
0
0
279
3152
0.64
4.08
4.2
4.5
4.5
4.5
mmol/l
0.06
251
2851
275
2333
1.54
4.06
6.8
3.8
21.8
13.9
mm/h
6.81
256
2092
34
164
2.17
4.05
8.5
3.3
25.9
25.2
mmol/l
0.52
34
158
277
3130
0.65
3.99
4.2
4.5
1.4
1.5
mmol/l
1.84
249
2805
32
152
2.20
3.96
3.1
3.7
216.4
1185.8
u/ml
0.53
25
131
42
222
1.99
3.95
3.1
2.2
4.1
12.6
nmol/l
9.62
37
202
95
649
1.60
3.75
2.0
1.8
1016.8
1172.8
nmol/l
0.80
78
487
14
45
3.19
3.68
2.1
1.4
—
—
—
0
0
14
45
3.19
3.68
2.0
1.4
—
—
—
0
0
14
45
3.19
3.68
2.1
1.4
—
—
—
0
0
14
45
3.19
3.68
2.0
1.4
—
—
—
0
0
267
3025
0.66
3.68
4.0
4.0
1.4
1.3
mmol/l
2.42
239
2690
290
3230
0.65
3.65
4.5
5.1
2.6
2.6
mmol/l
0.21
257
2895
14
46
3.12
3.56
2.0
1.4
—
—
—
0
0
9
17
5.39
3.53
1.1
2.2
—
—
—
0
0
5
191
0.25
3.49
1.6
1.9
—
—
—
0
0
16
58
2.83
3.46
1.7
1.6
—
—
—
0
0
38
204
1.95
3.44
7.5
2.9
117.9
125.8
g/l
1.37
38
197
8
14
5.80
3.35
1.1
1.1
—
—
—
0
0
18
71
2.61
3.34
3.2
2.8
16.4
16.0
%
0.17
11
37
19
78
2.51
3.26
1.2
1.4
—
—
—
0
0
344
3126
1.62
3.25
48.7
14.3
29.6
27.0
mg/l
0.77
327
2483
14
49
2.92
3.22
6.0
2.8
4.1
4.3
e9/l
0.15
14
49
13
44
3.02
3.16
2.2
1.4
—
—
—
0
0
30
153
2.04
3.13
10.1
4.1
49.6
47.2
%
0.20
30
147
11
34
3.30
3.08
1.6
1.4
—
—
—
0
0
11
34
3.30
3.08
2.0
3.7
3.2
4.4
nmol/l
0.47
11
34
13
46
2.89
2.94
1.2
1.2
—
—
—
0
0
6
9
6.74
2.87
1.5
1.6
—
—
—
0
0
272
3024
0.70
2.82
6.0
6.2
41.8
40.5
mmol/mol
1.26
251
2734
7
14
5.07
2.74
1.0
1.1
—
—
—
0
0
14
54
2.65
2.73
7.7
3.1
57.3
57.0
%
0.03
14
54
58
849
0.63
2.71
1.8
1.6
1.8
1.3
mmol/l
0.72
50
676
8
19
4.27
2.69
1.9
4.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
15
4.73
2.60
1.1
1.2
—
—
—
0
0
148
1184
1.39
2.57
7.0
3.8
—
—
—
0
0
109
828
1.43
2.54
7.3
3.7
0.0
0.0
estimate
0.50
37
269
110
845
1.41
2.39
1.9
1.5
17.1
20.9
nmol/l
2.25
100
696
5
8
6.31
2.38
1.0
1.1
—
—
—
0
0
33
195
1.75
2.27
4.2
2.6
0.3
0.3
e6/l
0.15
33
188
224
1940
1.34
2.26
4.0
3.0
65.8
54.9
u/l
0.85
206
1777
10
36
2.82
2.21
2.2
1.2
—
—
—
0
0
12
48
2.55
2.20
1.2
1.0
—
—
—
0
0
187
1582
1.33
2.19
3.4
2.5
—
—
—
0
0
16
76
2.15
2.05
1.3
1.2
—
—
—
0
0
6
15
4.04
2.04
2.3
3.2
—
—
—
0
0
46
307
1.56
2.01
3.0
2.2
6.9
7.7
ug/l
0.11
36
266
9
33
2.77
1.94
2.0
1.8
—
—
—
0
0
6
16
3.79
1.94
1.0
1.3
—
—
—
0
0
10
39
2.60
1.93
1.8
1.7
—
—
—
0
0
85
650
1.39
1.88
7.7
3.9
1.0
1.0
kg/l
0.31
12
102
5
12
4.20
1.83
1.2
1.0
—
—
—
0
0
8
29
2.79
1.80
2.5
3.8
—
—
—
0
0
15
75
2.04
1.71
1.3
1.2
—
—
—
0
0
295
3165
0.76
1.71
5.0
4.8
6.1
6.1
mmol/l
0.50
262
2804
53
379
1.46
1.70
6.1
3.2
—
—
—
0
0
8
31
2.61
1.66
1.0
1.4
—
—
—
0
0
5
14
3.60
1.62
2.4
1.6
—
—
—
0
0
5
14
3.60
1.62
1.4
1.4
—
—
—
0
0
7
26
2.72
1.58
2.0
1.7
—
—
—
0
0
6
21
2.88
1.51
1.0
1.6
—
—
—
0
0
7
29
2.44
1.40
2.4
2.0
—
—
—
0
0
15
82
1.86
1.37
1.3
1.3
—
—
—
0
0
16
90
1.81
1.35
2.4
1.4
—
—
—
0
0
75
595
1.32
1.32
1.2
1.2
1.2
1.3
u/ml
0.11
17
144
5
18
2.80
1.29
2.0
2.7
222.8
216.4
u/l
—
5
18
6
25
2.42
1.25
1.5
1.7
—
—
—
0
0
12
63
1.93
1.24
1.3
1.3
100.4
79.3
e6/l
—
7
48
12
63
1.93
1.24
1.2
1.2
27.5
17.6
e6/l
—
6
46
14
78
1.82
1.22
1.6
1.3
—
—
—
0
0
8
38
2.13
1.19
1.3
1.7
—
—
—
0
0
11
58
1.92
1.13
1.4
1.4
—
235.8
—
0
26
52
402
1.34
1.11
15.5
6.8
—
—
—
0
0
5
21
2.40
1.09
2.2
1.9
—
—
—
0
0
30
415
0.70
1.08
1.2
1.2
1.7
10.8
u/ml
—
6
139
158
1402
1.21
1.06
2.4
2.0
82.2
95.1
pmol/l
2.94
107
706
46
352
1.35
1.05
1.3
1.4
—
—
—
0
0
5
22
2.29
1.03
2.2
1.9
—
—
—
0
0
13
78
1.69
0.92
1.4
2.4
—
—
—
0
0
13
78
1.69
0.92
1.6
1.6
—
—
—
0
0
14
87
1.63
0.88
7.4
3.0
1.6
1.7
mg/l
0.26
14
79
23
162
1.44
0.86
1.1
1.2
20.2
173.9
iu/ml
—
7
58
17
113
1.53
0.83
1.1
1.1
—
—
—
0
0
293
2790
1.18
0.76
45.9
15.7
35.5
39.2
%
5.86
168
1818
247
2326
1.16
0.73
5.3
3.7
14.8
15.0
pmol/l
0.45
229
2052
17
117
1.47
0.73
1.3
1.4
—
—
—
0
0
5
25
2.01
0.73
2.4
1.4
—
—
—
0
0
7
43
1.64
0.67
1.0
1.0
1.6
1.5
g/l
—
7
38
5
28
1.80
0.66
1.0
1.0
—
—
—
0
0
29
228
1.29
0.60
5.2
2.9
62.4
57.8
ml/min/173m2
0.28
16
93
9
63
1.44
0.52
1.2
1.3
—
—
—
0
0
10
67
1.50
0.50
1.0
1.1
—
—
—
0
0
70
787
0.87
0.48
3.9
3.0
0.9
0.8
ug/l
0.21
52
562
5
31
1.62
0.43
1.0
1.1
—
—
—
0
0
344
3364
1.14
0.41
48.6
17.1
138.8
139.7
mmol/l
7.03
339
3246
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
344
3374
1.12
0.34
51.0
17.2
4.0
4.0
mmol/l
0.19
338
3251
143
1358
1.08
0.30
8.5
5.1
10.9
2.8
ug/l
1.78
128
1194
299
3055
0.92
0.28
41.2
14.2
77.4
75.7
ml/min/173m2
0.61
266
2491
81
756
1.09
0.25
2.2
1.9
433.8
16367028.9
pmol/l
0.78
70
611
11
87
1.27
0.24
1.3
1.6
—
—
—
0
0
5
39
1.29
0.23
1.0
1.1
—
—
—
0
0
42
460
0.90
0.22
4.6
4.6
33.1
31.7
%
0.53
29
300
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
114
1092
1.06
0.19
6.6
4.4
20.2
21.9
%
0.64
64
566
7
60
1.17
0.18
1.6
1.2
—
—
—
0
0
8
73
1.10
0.16
2.8
1.6
31.1
43.3
nmol/l
—
8
67
29
268
1.09
0.12
1.8
1.8
1.7
1.6
%
0.35
22
231
292
2887
1.04
0.11
5.9
4.5
11.7
2.0
mu/l
0.50
263
2547
43
449
0.95
0.08
1.2
1.2
10.3
36.5
iu/ml
—
9
137
8
76
1.05
0.07
1.0
1.1
—
18.6
—
0
10
32
331
0.96
0.03
1.4
1.5
—
—
—
0
0
338
3390
0.98
0.02
31.3
10.3
25.5
24.5
u/l
0.53
332
3233
14
133
1.05
0.01
1.4
1.7
—
—
—
0
0
111
1107
1.00
0.00
4.1
4.1
15.8
8.4
mg/mmol
0.77
75
696
12
124
0.97
0.00
1.1
1.6
—
—
—
0
0
5
54
0.93
0.00
1.2
1.5
—
—
—
0
0
5
56
0.89
0.00
3.4
1.7
142.6
207.8
pmol/l
—
5
50
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
9
0.00
0.00
0.0
1.1
—
117.2
—
0
9
0
6
0.00
0.00
0.0
3.5
—
106.1
—
0
6
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
8.6
—
0
6
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
0.00
0.0
4.2
—
0.6
—
0
5
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
116.8
—
0
5
0
5
0.00
0.00
0.0
1.0
—
100.0
—
0
5
0
6
0.00
0.00
0.0
1.2
—
114.0
—
0
6
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
20.9
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint M13_SPONDYLOPATHINOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_SPONDYLOPATHINOTH | 5.167 [4.07, 6.56] | < 0.001 |
| Birth year | 0.999 [0.99, 1.01] | 0.863 |
During the follow-up period (1.1.1998 — 31.12.2019), 652 out of 1121 females with M13_SPONDYLOPATHINOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_SPONDYLOPATHINOTH | 5.293 [4.03, 6.95] | < 0.001 |
| Birth year | 0.985 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 776 out of 1200 males with M13_SPONDYLOPATHINOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_SPONDYLOPATHINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.484% | 0.855% |
| 5 | 3.033% | 5.448% |
| 10 | 7.674% | 13.902% |
| 15 | 14.248% | 24.854% |
| 20 | 24.02% | 38.395% |
Relationships between endpoints
↥Index endpoint: M13_SPONDYLOPATHINOTH – Spondylopathies in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data